Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Alpha-Synuclein (alphaSyn or SNCA) Overview | 9 | 1 |
| Therapeutics Development | 10 | 3 |
| Alpha-Synuclein (alphaSyn or SNCA) Products under Development by Stage of Development | 10 | 1 |
| Alpha-Synuclein (alphaSyn or SNCA) Products under Development by Therapy Area | 11 | 1 |
| Alpha-Synuclein (alphaSyn or SNCA) Products under Development by Indication | 12 | 1 |
| Alpha-Synuclein (alphaSyn or SNCA) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Alpha-Synuclein (alphaSyn or SNCA) Products under Development by Companies | 15 | 3 |
| Alpha-Synuclein (alphaSyn or SNCA) Products under Development by Universities/Institutes | 18 | 2 |
| Alpha-Synuclein (alphaSyn or SNCA) Therapeutics Assessment | 20 | 6 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Mechanism of Action | 21 | 1 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Alpha-Synuclein (alphaSyn or SNCA) Companies Involved in Therapeutics Development | 26 | 12 |
| AC Immune SA | 26 | 1 |
| AFFiRiS AG | 27 | 1 |
| BioArctic Neuroscience AB | 28 | 1 |
| Biogen, Inc. | 29 | 1 |
| NeuroPhage Pharmaceuticals, Inc. | 30 | 1 |
| Neuropore Therapies, Inc. | 31 | 1 |
| nLife Therapeutics, S.L. | 32 | 1 |
| Primary Peptides, Inc. | 33 | 1 |
| Prothena Corporation Plc | 34 | 1 |
| QR Pharma, Inc. | 35 | 1 |
| reMYND NV | 36 | 1 |
| Synovo GmbH | 37 | 1 |
| Alpha-Synuclein (alphaSyn or SNCA) Drug Profiles | 38 | 34 |
| BAN-0805 Drug Profile | 38 | 1 |
| BIIB-054 Drug Profile | 39 | 1 |
| CLR-01 Drug Profile | 40 | 1 |
| DPC-003 Drug Profile | 41 | 1 |
| Kenterin Drug Profile | 42 | 1 |
| Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases Drug Profile | 43 | 1 |
| NLFPD-1233 Drug Profile | 44 | 1 |
| NPT-001 Drug Profile | 45 | 2 |
| NPT-002 Drug Profile | 47 | 1 |
| NPT-005 Drug Profile | 48 | 1 |
| NPT-088 Drug Profile | 49 | 1 |
| NPT-133 Drug Profile | 50 | 1 |
| NPT-20011 Drug Profile | 51 | 1 |
| NPT-3G Drug Profile | 52 | 1 |
| PD-01 Drug Profile | 53 | 2 |
| PD-03 Drug Profile | 55 | 1 |
| PD-04 Drug Profile | 56 | 1 |
| Posiphen Drug Profile | 57 | 3 |
| PP-003 Drug Profile | 60 | 1 |
| PRX-002 Drug Profile | 61 | 2 |
| quinpramine Drug Profile | 63 | 1 |
| ReS-12S Drug Profile | 64 | 1 |
| ReS-9S Drug Profile | 65 | 1 |
| Small Molecule to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease Drug Profile | 66 | 1 |
| Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease Drug Profile | 67 | 1 |
| Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease Drug Profile | 68 | 1 |
| trehalose Drug Profile | 69 | 1 |
| Vaccine to Target Alpha-Synuclein for Neurodegenerative Disease Drug Profile | 70 | 1 |
| Vaccine to Target Alpha-Synuclein for Parkinson's Disease Drug Profile | 71 | 1 |
| Alpha-Synuclein (alphaSyn or SNCA) Dormant Projects | 72 | 2 |
| Alpha-Synuclein (alphaSyn or SNCA) Featured News &Press Releases | 74 | 9 |
| Mar 22, 2016: Neuropore Announces Successful Completion of Phase I with its Lead Compound NPT200-11 | 74 | 1 |
| Aug 12, 2015: Neuropore Therapies Commences Phase 1 Clinical Trials | 74 | 1 |
| Jul 19, 2015: NeuroPhage's NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer's Association International Conference | 74 | 1 |
| Jul 13, 2015: NeuroPhage to be Featured in Oral Session at the 2015 Alzheimer s Association International Conference | 75 | 1 |
| Jul 02, 2015: BIIB054 reached significant milestone | 75 | 1 |
| Jun 17, 2015: Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease | 75 | 1 |
| Jun 15, 2015: BioArctic Neuroscience Parkinson s disease program receives grant from VINNOVA | 76 | 1 |
| Jun 08, 2015: Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders | 77 | 1 |
| Apr 02, 2015: 2nd US patent granted on therapeutic antibodies for Parkinson s disease | 77 | 1 |
| Mar 19, 2015: Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson's Disease | 77 | 2 |
| Mar 16, 2015: NeuroPhage to Present at 12th International Conference on Alzheimer s &Parkinson s Diseases | 79 | 1 |
| Dec 09, 2014: Parkinson's Vaccine: EU-Team Launches Clinical Trial Vaccine candidate based on proprietary technology by AFFiRiS | 79 | 1 |
| Nov 14, 2014: NeuroPhage s GAIM Technology Chosen As Top Project To Watch For The Therapeutic Area Partnerships Conference | 80 | 1 |
| Aug 26, 2014: Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress | 80 | 1 |
| Jul 31, 2014: First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development | 81 | 2 |
| Appendix | 83 | 2 |
| Methodology | 83 | 1 |
| Coverage | 83 | 1 |
| Secondary Research | 83 | 1 |
| Primary Research | 83 | 1 |
| Expert Panel Validation | 83 | 1 |
| Contact Us | 83 | 1 |
| Disclaimer | 84 | 1 |